| Autor: |
PEDRAZ, CARMEN, CARBONELL-ESTRANY, XAVIER, FIGUERAS-ALOY, JOSÉ, QUERO, JOSÉ |
| Zdroj: |
The Pediatric Infectious Disease Journal; September 2003, Vol. 22 Issue: 9 p823-827, 5p |
| Abstrakt: |
Respiratory syncytial virus (RSV) is a major cause of hospitalization in preterm infants and infants with chronic lung disease (CLD). Palivizumab, a humanized monoclonal antibody, was approved in Europe in 1999 as prophylaxis against severe RSV-related respiratory illness. No multiple season data have been published on palivizumab effectiveness in European populations. Data collected during 4 years in Spain compared RSV hospitalization rates and risk factors in a cohort of palivizumab-prophylaxed and nonprophylaxed preterm infants. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
